• Linux Laboratories has secured a $70 million equity deal with ChrysCapital and Tata Capital Healthcare Fund III.
• Linux Laboratories plans further investment in manufacturing and R&D alongside brand acquisitions and expansion into additional therapies.

Linux Laboratories, a Chennai, India-based pharmaceutical formulations company with a nutraceutical portfolio and its own manufacturing business, announced on September 29, 2026, that it had secured a $70 million equity transaction with ChrysCapital and Tata Capital Healthcare Fund III.

The deal combines primary capital with a secondary share purchase, giving ChrysCapital a minority stake and allowing Tata Capital Healthcare Fund II to exit at approximately four times its investment. The total therefore includes both funding for the company and payments for existing shares. Avendus Capital advised Linux on the transaction.

Manufacturing investment is among the stated uses of proceeds, alongside R&D, acquisitions and expansion into additional therapeutic areas. Linux’s Pondicherry manufacturing subsidiary serves outside clients as well as the group’s own brands. Its facilities manufacture pharmaceutical and nutraceutical products, while its business model includes production under customers’ brand names and technology transfer.

Founded in 2007, Linux built its business around central nervous system therapies before expanding into dermatology, cardio-diabetics and nutraceuticals. Its portfolio now comprises more than 125 brands and approximately 400 stock-keeping units. The manufacturing operation gives the group an in-house production base alongside a contract manufacturing business serving domestic and international clients.

Discussing the planned expansion, K Keerthivasan, Linux’s co-founder and executive director, said: “This capital marks an important milestone, enabling us to expand our capacity and scale our business.” Linux has not disclosed the primary-capital allocation or the amount earmarked for nutraceutical manufacturing.